HSulf-1 inhibits angiogenesis and tumorigenesis in vivo

被引:121
作者
Narita, Keishi
Staub, Julie
Chien, Jeremy
Meyer, Kristy
Bauer, Maret
Friedl, Andreas
Ramakrishnan, Sundaram
Shridhar, Viji
机构
[1] Mayo Clin, Ctr Canc, Dept Expt Pathol, Rochester, MN 55905 USA
[2] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA
[3] Univ Minnesota, Dept Pharmacol, Minneapolis, MN USA
关键词
D O I
10.1158/0008-5472.CAN-05-3582
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously identified HSulf-1 as a down-regulated gene in several tumor types including ovarian, breast, and hepatocellular carcinomas. Loss of HSulf-1, which selectively removes O-sulfate from heparan sulfate, up-regulates heparin-binding growth factor signaling and confers resistance to chemotherapy-induced apoptosis. Here we report that HSulf-1 expression in MDA-MB-468 breast carcinoma clonal lines leads to reduced proliferation in vitro and reduced tumor burden in athymic nude mice in vivo. Additionally, xenografts derived from HSulf-1-expressing stable clones of carcinoma cells showed reduced vessel density, marked necrosis, and apoptosis, indicative of inhibition of angiogenesis. Consistent with this observation, HSulf-1-expressing clonal lines showed reduced staining with the endothelial marker CD31 in Matrigel plug assay, indicating that HSulf-1 expression inhibits angiogenesis. More importantly, HSulf-1 expression in the xenografts was associated with a reduced ability of vascular endothelial cell heparan sulfate to participate in a complex with fibroblast growth factor 2 (FGF-2) and its receptor tyrosine kinase FGF receptor Ic. In vitro, short hairpin RNA-mediated down-regulation of HSulf-1 in human umbilical vein endothelial cells (HUVEC) resulted in an increased proliferation mediated by heparan sulfate-dependent FGF-2, hepatocyte growth factor, and vascular endothelial growth factor 165 (VEGF(165)) but not by heparan sulfate-independent VEGF(121)(.)HSulf-1 down-regulation also enhanced downstream signaling through the extracellular signal-regulated kinase pathway compared with untreated cells. Consistent with the role of heparan sulfate glycosaminoglycan sulfation in VEGF-mediated signaling, treatment of HUVEC cells with chlorate, which inhibits heparan sulfate glycosaminoglycan sulfation and therefore mimics HSulf-1 overexpression, led to an allenuated VEGF-mediated signaling. Collectively, these observations provide the first evidence of a novel mechanism by which HSuIf-1 modulates the function of heparan sulfate binding VEGF165 in proliferation and angiogenesis.
引用
收藏
页码:6025 / 6032
页数:8
相关论文
共 38 条
[1]   A large-scale RNAi screen in human cells identifies new components of the p53 pathway [J].
Berns, K ;
Hijmans, EM ;
Mullenders, J ;
Brummelkamp, TR ;
Velds, A ;
Heimerikx, M ;
Kerkhoven, RM ;
Madiredjo, M ;
Nijkamp, W ;
Weigelt, B ;
Agami, R ;
Ge, W ;
Cavet, G ;
Linsley, PS ;
Beijersbergen, RL ;
Bernards, R .
NATURE, 2004, 428 (6981) :431-437
[2]  
Borgström P, 1999, ANTICANCER RES, V19, P4203
[3]   Angiogenesis in cancer and other diseases [J].
Carmeliet, P ;
Jain, RK .
NATURE, 2000, 407 (6801) :249-257
[4]   Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ [J].
Chang, Z ;
Meyer, K ;
Rapraeger, AC ;
Friedl, A .
FASEB JOURNAL, 2000, 14 (01) :137-144
[5]   A unique role for 6-O sulfation modification in zebrafish vascular development [J].
Chen, E ;
Stringer, SE ;
Rusch, MA ;
Selleck, SB ;
Ekker, SC .
DEVELOPMENTAL BIOLOGY, 2005, 284 (02) :364-376
[6]  
Chien J, 2001, INT J CANCER, V91, P46, DOI 10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO
[7]  
2-0
[8]  
Clayton A, 2001, KIDNEY INT, V59, P2084, DOI 10.1046/j.1523-1755.2001.00723.x
[9]   HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo [J].
Dai, YM ;
Yang, Y ;
MacLeod, V ;
Yue, XP ;
Rapraeger, AC ;
Shriver, Z ;
Venkataraman, G ;
Sasisekharan, R ;
Sanderson, RD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (48) :40066-40073
[10]   Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy [J].
Ferrara, N ;
Hillan, KJ ;
Novotny, W .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (02) :328-335